17 and older, any sex, with Depressive Symptoms. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Percentage of Eligible Participants Who Agreed to Participate in the TrialPrimary· Up to 10 days after screening survey
Of the individuals meeting eligibility criteria (i.e., mild-to-moderate depressive symptoms, no current mental health service utilization) from the initial screen, what percentage agreed to be enrolled and randomized into the clinical trial.
Group
Value
95% CI
Eligible Participants
120
Percentage of Participants Who Completed Follow-upsPrimary· Baseline up to six-week follow-up
Weekly ten-minute surveys assessing mental health symptoms, stress, and adaptive functioning were sent to participants. Results reflect the number of participants who completed their survey each week.
Week 1
Group
Value
95% CI
Assessment Only
23
Intervention
81
Week 2
Group
Value
95% CI
Assessment Only
23
Intervention
80
Week 3
Group
Value
95% CI
Assessment Only
24
Intervention
79
Week 4
Group
Value
95% CI
Assessment Only
25
Intervention
78
Week 5
Group
Value
95% CI
Assessment Only
24
Intervention
76
Week 6
Group
Value
95% CI
Assessment Only
26
Intervention
78
Percentage of Participants That Remain Active (i.e. do Not Request to Stop Messages) on the Text-message GroupPrimary· Baseline up to six-week follow-up
Results reflect the participants who remained active during the full trial in the intervention group.
Group
Value
95% CI
Intervention
88
Number of WithdrawalsPrimary· Baseline up to six-week follow-up
Results reflect participants who requested to withdraw from the trial.
Group
Value
95% CI
Assessment Only
0
Intervention
2
Total Percent of Feedback Reports That Were Viewed Across All Sent Feedback ReportsPrimary· Baseline up to six-week follow-up
As part of the intervention arm, participants were randomized each week to receive or not receive personalized feedback reports. Reports had graphical explanations of the participant's responses to the survey questions. The data values reported reflect the number of participants who viewed feedback reports, while the Number Analyzed for each Row reflects the number of participants who were sent a personalized feedback report that week.
Week 1
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
37
Week 2
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
34
Week 3
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
29
Week 4
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
30
Week 5
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
26
Week 6
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
29
Percent of Participants (in the Intervention Arm) That Viewed a Personalized Feedback Report at Least OncePrimary· Baseline up to six-week follow-up
As part of the intervention, some participants in the intervention arm were randomly sent feedback reports. Reports had graphical explanations of the participant's response to the survey questions. All participants in the intervention arm were sent at least one feedback report during the course of the trial. Results reflect the number of participants who viewed at least one report.
Group
Value
95% CI
Intervention - Surveys, Text Messages, and Feedback Reports
70
Participant Self-reported Satisfaction With the Intervention Components - Assessment-onlyPrimary· Six-week follow-up
Participants in the "Assessment Only" arm who completed the 6-week follow-up survey responded to an 8-question survey regarding their satisfaction with the study. Each question was on a scale of 1 to 7 (1-Strongly disagree, 4 Neither agree nor disagree, 7-Strongly Agree). A higher score indicated more satisfaction with the study. Results reflect the average participant scores for each question.
I am glad I participated in the study.
Group
Value
95% CI
Assessment Only
6.12
± 0.77
The weekly Sunday surveys helped me to reflect on how things were going in my life.
Group
Value
95% CI
Assessment Only
6.00
± 0.82
I would be willing to complete brief (~5 minute) weekly surveys during the year without compensation
Group
Value
95% CI
Assessment Only
3.24
± 1.64
My confidentiality and privacy was respected during this study.
Group
Value
95% CI
Assessment Only
6.20
± 0.87
Six weeks was too brief for this study period.
Group
Value
95% CI
Assessment Only
4.12
± 1.30
Participating in this study was beneficial for my health and well-being.
Group
Value
95% CI
Assessment Only
5.16
± 1.14
The system of receiving messages and completing surveys was convenient.
Group
Value
95% CI
Assessment Only
6.40
± 0.91
I liked participating in this study.
Group
Value
95% CI
Assessment Only
6.04
± 1.02
Participant Self-reported Satisfaction With the Intervention Components - Intervention OnlyPrimary· Six-week follow-up
Participants in the "Intervention" arm who completed the 6-week follow-up survey responded to an 18-question survey regarding their satisfaction with the intervention. Each question was on a scale of 1 to 7 (1-Strongly disagree, 4 Neither agree nor disagree, 7-Strongly Agree). A higher score indicated more satisfaction. Results reflect the average participant scores for each question.
I am glad that I participated in this study.
Group
Value
95% CI
Intervention
6.18
± 1.00
The daily 5-item surveys helped me to reflect on how things were going in my life.
Group
Value
95% CI
Intervention
5.90
± 1.11
The coping/support text-message strategies were useful for me.
Group
Value
95% CI
Intervention
4.31
± 1.73
I would be willing to complete brief (~5 minute) weekly surveys during the year without compensation
Group
Value
95% CI
Intervention
4.04
± 1.71
The personalized feedback reports provided valuable insight into how I was doing over time.
Group
Value
95% CI
Intervention
5.25
± 1.23
The number of coping/support text messages I received was… (1-too few, 4-just right, 7-too many)
Group
Value
95% CI
Intervention
4.18
± 1.36
Six weeks was too brief for this study period.
Group
Value
95% CI
Intervention
4.26
± 1.41
Participating in this study was beneficial for my health and well-being.
Group
Value
95% CI
Intervention
5.18
± 0.93
Adverse events — posted to ClinicalTrials.gov
Time frame: 6 weeks.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This research study is being conducted to better understand how college students develop and cope with stress and to identify opportunities to help students notice and respond to stress early before symptoms contribute to significant negative consequences.
This project will be completed in two parts. In the first part (not a trial) participants will be asked to complete a screening survey to determine eligibility. Eligible participants (i.e., those with mild-to-moderate depressive symptoms and not receiving mental health care) will continue into the clinical trial portion (part two). There were 120 students in the clinical trial phase of the study, where 30 were randomly assigned to "assessment only" and 90 to the "intervention" condition.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07407686 — Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services
· not yet recruiting
NCT07137468 — Everyday Exposures: How Chemicals and Weight Impact Breast Cancer Risk
· recruiting
NCT07010081 — Using Digital Health in a Postoperative Setting After Major Surgery: Survey Study
· NA
· recruiting
NCT06962995 — Multi-Cancer Detection Observational Cohort Study
· recruiting
NCT06960499 — Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy
· not yet recruiting
Other recruiting trials for Depressive Symptoms
Currently open trials in the same condition.
NCT07299903 — IMB-Based Sleep Hygiene Education for Menopausal Women: Effects on Sleep Quality and Depression
· NA
· recruiting
NCT07413692 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Urinary Incontinence in Postpartum and E
· NA
· recruiting
NCT07413705 — BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and
· NA
· recruiting
NCT07241325 — Psychological Well-Being, Depression, and Health-Related Quality of Life in Adults With Type 2 Diabetes: A Cross-Section
· recruiting
NCT07216326 — Our Voices Matter: Intervention for Depression in Youth
· NA
· recruiting
Other University of Michigan trials
Trials by the same sponsor.
NCT07536919 — Integrating Care for Hypertension-Diabetes MULTImorbidity in Guatemala Through HEARTS Implementation
· NA
· not yet recruiting
NCT05509842 — Function-based Accelerated Stimulation Therapy (FAST-therapy) for Freezing of Gait (FOG) After Parkinson's Disease (PD)
· NA
· not yet recruiting
NCT06311188 — Exploring PTSD Symptoms, Barriers and Facilitators to Mindfulness
· NA
· not yet recruiting
NCT07471646 — Effects of Ramadan Fasting With Exercise on Cardiometabolic Health
· NA
· not yet recruiting
NCT06671925 — A Community Health Worker-Led Program for Chronic Pain and Loneliness in Older Adults
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Michigan
Last refreshed: 4 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06583096.